Mitostatic Compounds Modulate Mitochondrial Dynamics in Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for neurodegenerative disorders like Alzheimer's disease and Parkinson's disease primarily focus on increasing brain glucose metabolism, lacking compounds that effectively address mitochondrial dynamics and function, which are severely impaired in these conditions, leading to mitochondrial fragmentation, reduced content, and impaired bioenergetic functions.
Innovation Solution
An in vitro method for assessing test agents' potential as mitotherapeutics, involving labeling mitochondria in brain cells, imaging, and analyzing parameters like mitochondrial concentration, length, and circularity to determine their effectiveness in modulating mitochondrial health and function, along with a list of compounds that can be administered to treat disorders related to neuronal mitostasis and ATP generation dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If current therapeutics focus on increasing brain glucose metabolism, then energy supply to brain cells is improved, but mitochondrial dynamics and function remain severely impaired leading to fragmentation and reduced content
Solution Approach 1:
The patent changes the therapeutic parameter from glucose metabolism enhancement to direct mitochondrial dynamics modulation. It identifies and tests compounds that specifically target mitochondrial fission/fusion processes, transitioning the approach from metabolic support to structural-functional restoration of mitochondria in neurodegenerative disorders
Solution Approach 2:
The patent introduces mitochondrial dynamics-modulating compounds as intermediaries between the therapeutic agent and the mitochondrial system. These compounds act as mediators that directly influence mitochondrial fission and fusion processes, bridging the gap between external treatment and internal mitochondrial function restoration
2Quantity of substance
If mitochondrial content and length are increased through fusion enhancement, then mitochondrial health and ATP production are improved, but the complexity of identifying and testing such compounds is high
Solution Approach 1:
The patent replaces complex, multi-step mechanical screening processes with a simplified assay system using primary neuronal cultures and automated imaging. The high-content screening methodology substitutes traditional labor-intensive tests with image-based quantification of mitochondrial parameters, reducing operational complexity while maintaining detection sensitivity
Solution Approach 2:
The patent uses primary neuronal cultures as in vitro models that copy and mimic in vivo mitochondrial behavior. This cellular model system replicates the complex mitochondrial dynamics of actual neurons, allowing screening of compounds without requiring direct human tissue testing, thus simplifying the development process while preserving biological relevance
Data Source
AI summary
Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.